pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostaty, nádorů, kastrace-odolné - terapeutické radiofarmaky - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
citalopram +pharma 20mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 10628 citalopram-hydrobromid - potahovaná tableta - 20mg - citalopram
paroxetin +pharma 20mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 12795 paroxetin-hydrochlorid - potahovaná tableta - 20mg - paroxetin
xyzal 5mg potahovaná tableta
ucb s.r.o., praha array - 16445 levocetirizin-dihydrochlorid - potahovaná tableta - 5mg - levocetirizin
zyrtec 10mg/ml perorální kapky, roztok
ucb s.r.o., praha array - 12076 cetirizin-dihydrochlorid - perorální kapky, roztok - 10mg/ml - cetirizin
zyrtec 10mg potahovaná tableta
ucb s.r.o., praha array - 12076 cetirizin-dihydrochlorid - potahovaná tableta - 10mg - cetirizin